Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
Completed
Novartis
Phase 3
2007-07-01
This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose
combination in adults with moderate, inadequately controlled hypertension. There was an
optional study extension for eligible patients who wanted to participate that contains the
triple therapy (ie, hydrochlorothiazide+ amlodipine/valsartan).
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
Completed
Novartis
Phase 4
2009-06-01
The purpose of the study was to assess efficacy and safety of fixed dose combination of 5 mg
amlodipine/80 mg valsartan compared to 160 mg valsartan monotherapy in lowering blood
pressure in Taiwanese patients.
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
Completed
Novartis
Phase 4
2010-05-01
The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine
(EXforge®) with nifedipine, as well as vascular function index.
Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Completed
CJ HealthCare Corporation
Phase 1
2012-02-01
The objectives of this study are:
- To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge
10/160mg after a single oral administration in healthy male volunteers
- To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis
Exforge 10/160mg after a single oral administration in healthy male volunteers
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
